<DOC>
	<DOCNO>NCT00045565</DOCNO>
	<brief_summary>This phase I trial study side effect best dose arsenic trioxide radiation therapy treat patient newly diagnose malignant glioma . Drugs arsenic trioxide may stop growth malignant glioma stop blood flow tumor . Radiation therapy use high-energy x-rays damage tumor cell . Combining arsenic trioxide radiation therapy may kill tumor cell .</brief_summary>
	<brief_title>Arsenic Trioxide Plus Radiation Therapy Treating Patients With Newly Diagnosed Malignant Glioma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerate dose ( MTD ) Arsenic Trioxide ( ATO ) administer week schedule twice week schedule conjunction radiation therapy patient newly diagnose glioblastoma multiforme . II . To determine toxicity ATO administer week schedule twice week schedule conjunction radiation therapy patient newly diagnose glioblastoma multiforme . SECONDARY OBJECTIVES : I . To determine survival patient newly diagnose glioblastoma multiforme receive ATO administer week schedule twice week schedule conjunction radiation therapy . II . To evaluate effect ATO tumor vasculature use perfusion MRI . III . To describe pharmacokinetics ATO follow weekly twice weekly injection . OUTLINE : This nonrandomized , open-label , multicenter , dose-escalation study arsenic trioxide . Patients assign 1 2 treatment group . Group A : Patients receive arsenic trioxide IV 2 hour weekly 6 week . Group B : Patients receive arsenic trioxide lower dose IV 2 hour twice weekly 6 week . Patients group also undergo radiotherapy daily 5 day week 6 week . In group , cohort 3-6 patient receive escalate dos arsenic trioxide maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 3 6 patient experience dose-limiting toxicity . Patients follow weekly 4 week every 2 month thereafter .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>Patients must histologically confirm supratentorial grade IV astrocytoma ( glioblastoma multiforme ) Patients must receive prior radiation therapy , chemotherapy , immunotherapy therapy biologic agent ( include immunotoxins , immunoconjugates , antisense , peptide receptor antagonist , interferon , interleukin , TIL , LAK gene therapy ) , hormonal therapy brain tumor ; glucocorticoid therapy allow Patients must recover immediate postoperative period maintain stable corticosteroid regimen ( increase 5 day ) prior start treatment Absolute neutrophil count 1500/mm^3 Platelets 100,000/mm^3 Creatinine = &lt; 1.5 mg/dL Total bilirubin &lt; 2 mg/dl Transaminases &lt; 4 time upper limit institutional normal Serum potassium &gt; 3.0 &lt; 5.5mEq/l Magnesium &gt; 1.2 &lt; 2.5 mEq/l Patients must give informed consent understand investigational nature study potential risk benefit Patients must pregnant breastfeeding ; patient potential pregnancy counsel request follow acceptable birth control method avoid conception ; patient pregnant breastfeed exclude information agent exist regard safety fetus breastfeed infant Patients must Karnofsky performance status &gt; = 60 % No serious concurrent infection medical illness present would jeopardize ability patient receive therapy outline protocol reasonable safety Patients must mini mental score &gt; = 15 Patients prior malignancy ; patient curatively treat carcinoma situ basal cell carcinoma skin patient free disease &gt; = five year eligible study Patients pregnant breastfeeding ; patient exclude information agent exist regard safety fetus breastfeed infant Prior therapy ( surgery exclude ) brain tumor Patients seconddegree heart block Patients treat Amphotericin B Patients undergo MRI eligible study Patients currently take drug know prolong QT interval ; order eligible patient need drug &gt; = 5 day prior start treatment ; patient may resume drug &gt; 2 week last ATO treatment ; QT prolongation continue 5 day post drug discontinuation , patient eligible ATO treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>